Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
10 janv. 2022 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
INVECTYS INC. TO PARTICIPATE IN THE 2022 JP MORGAN HEALTHCARE MEETING AND BIOTECH SHOWCASE, JANUARY 10-19, 2022
05 janv. 2022 09h00 HE
|
Invectys, Inc.
Houston, Texas, USA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...
Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference
23 déc. 2021 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™
14 déc. 2021 08h18 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), with a mission to discover and develop innovative and revolutionary...
Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
11 janv. 2021 07h46 HE
|
Cyclacel
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by...
Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance
05 janv. 2021 09h44 HE
|
Cognition Therapeutics, Inc.
Pittsburgh, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021
30 déc. 2020 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
13 janv. 2020 07h00 HE
|
Cyclacel
– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML/MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. ...
Incysus Therapeutics to Present at Biotech Showcase 2020
09 janv. 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco
06 janv. 2020 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...